Literature DB >> 3027300

Diuretic actions in man of a selective kappa opioid agonist: U-62,066E.

G R Peters, N J Ward, E G Antal, P Y Lai, E W deMaar.   

Abstract

The effect of a selective kappa opioid agonist, U-62,066E, on urine formation in human volunteers was assessed. Volunteers received single intramuscular injections of either placebo or 2, 3, 4, 5 or 6 micrograms/kg of U-62,066E in a randomized, double-blind study. U-62,066E caused dose-dependent maximal increases in urine volume of 2.6 times control in the first 4 hr after administration. A corresponding decrease in urine osmolality to 20% of base-line values occurred. No changes in total urinary Na, K or Cl excretion were identified. Kappa agonists produce a water-only diuresis at low doses in humans. The mechanism of this effect was not examined in this study but probably relates to alterations in antidiuretic hormone activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3027300

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Neuroprotective actions of GR89696, a highly potent and selective kappa-opioid receptor agonist.

Authors:  P J Birch; H Rogers; A G Hayes; N J Hayward; M B Tyers; D I Scopes; A Naylor; D B Judd
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

2.  Effects of butorphanol on morphine-induced itch and analgesia in primates.

Authors:  Heeseung Lee; Norah N Naughton; James H Woods; Mei-Chuan Ko
Journal:  Anesthesiology       Date:  2007-09       Impact factor: 7.892

3.  Controlling signaling with a specifically designed Gi-coupled receptor.

Authors:  P Coward; H G Wada; M S Falk; S D Chan; F Meng; H Akil; B R Conklin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

4.  The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist.

Authors:  G H Rimoy; D M Wright; N K Bhaskar; P C Rubin
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man.

Authors:  H J Kramer; W Uhl; B Ladstetter; A Bäcker
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

6.  Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.

Authors:  Vanessa Minervini; Sujata Dahal; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2016-11-30       Impact factor: 4.030

Review 7.  Neuraxial opioid-induced itch and its pharmacological antagonism.

Authors:  Mei-Chuan Ko
Journal:  Handb Exp Pharmacol       Date:  2015

8.  Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures.

Authors:  Vanessa Minervini; Hannah Y Lu; Jahnavi Padarti; Daniela C Osteicoechea; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2018-05-22       Impact factor: 4.530

Review 9.  The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.

Authors:  David Mysels; Maria A Sullivan
Journal:  Am J Addict       Date:  2009 Jul-Aug

10.  Mechanism of diuretic action of spiradoline (U-62066E)--a kappa opioid receptor agonist in the human.

Authors:  G H Rimoy; N K Bhaskar; D M Wright; P C Rubin
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.